Zosano Pharma Corp Company Profile (NASDAQ:ZSAN)

About Zosano Pharma Corp (NASDAQ:ZSAN)

Zosano Pharma Corp logoZosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability. The Company's short-wear-time transdermal patch consists of an array of titanium microneedles that is coated with its formulation of an approved drug and attached to an adhesive patch. When the patch is applied with its hand-held applicator, the microneedles painlessly penetrate the skin, resulting in rapid dissolution and absorption of the drug coating through the capillary bed. Its product candidates include ZP-Triptan, ZP-Glucagon and ZP-PTH. ZP-PTH is a formulation of teriparatide, a synthetic form of parathyroid hormone. ZP-Glucagon is a formulation of glucagon.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ZSAN
  • CUSIP: N/A
  • Web: www.zosanopharma.com
Capitalization:
  • Market Cap: $58.41 million
  • Outstanding Shares: 39,200,000
Average Prices:
  • 50 Day Moving Avg: $1.49
  • 200 Day Moving Avg: $1.39
  • 52 Week Range: $0.45 - $3.54
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.82
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.73 per share
  • Price / Book: 2.04
Profitability:
  • EBIDTA: ($24,630,000.00)
  • Return on Equity: -170.32%
  • Return on Assets: -82.84%
Debt:
  • Current Ratio: 2.38%
  • Quick Ratio: 2.38%
Misc:
  • Average Volume: 1.41 million shs.
  • Beta: 1.19
  • Short Ratio: 0.44
 

Frequently Asked Questions for Zosano Pharma Corp (NASDAQ:ZSAN)

What is Zosano Pharma Corp's stock symbol?

Zosano Pharma Corp trades on the NASDAQ under the ticker symbol "ZSAN."

How were Zosano Pharma Corp's earnings last quarter?

Zosano Pharma Corp (NASDAQ:ZSAN) posted its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.30) by $0.04. View Zosano Pharma Corp's Earnings History.

Where is Zosano Pharma Corp's stock going? Where will Zosano Pharma Corp's stock price be in 2017?

3 analysts have issued 12-month price objectives for Zosano Pharma Corp's shares. Their predictions range from $3.00 to $4.00. On average, they anticipate Zosano Pharma Corp's stock price to reach $3.50 in the next year. View Analyst Ratings for Zosano Pharma Corp.

Are investors shorting Zosano Pharma Corp?

Zosano Pharma Corp saw a increase in short interest during the month of April. As of April 13th, there was short interest totalling 2,838,505 shares, an increase of 35.1% from the March 31st total of 2,101,728 shares. Based on an average daily volume of 912,958 shares, the days-to-cover ratio is currently 3.1 days. Approximately 12.2% of the shares of the company are short sold.

Who are some of Zosano Pharma Corp's key competitors?

When did Zosano Pharma Corp IPO?

(ZSAN) raised $47 million in an IPO on Tuesday, January 27th 2015. The company issued 4,300,000 shares at $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners acted as the underwriters for the IPO.

Who owns Zosano Pharma Corp stock?

Zosano Pharma Corp's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include ROSALIND ADVISORS, INC. (5.50%), FMR LLC (9.13%), Vanguard Group Inc. (5.18%), Endurant Capital Management LP (2.94%), Perceptive Advisors LLC (2.46%) and Nexthera Capital LP (2.46%). Company insiders that own Zosano Pharma Corp stock include Donald J Kellerman, Enterprise Associates 12 New, Georgia Erbez, John Peter Walker, Konstantinos Alataris and M James Barrett. View Institutional Ownership Trends for Zosano Pharma Corp.

Who sold Zosano Pharma Corp stock? Who is selling Zosano Pharma Corp stock?

Zosano Pharma Corp's stock was sold by a variety of institutional investors in the last quarter, including Geneva Advisors LLC. Company insiders that have sold Zosano Pharma Corp stock in the last year include Enterprise Associates 12 New and M James Barrett. View Insider Buying and Selling for Zosano Pharma Corp.

Who bought Zosano Pharma Corp stock? Who is buying Zosano Pharma Corp stock?

Zosano Pharma Corp's stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Endurant Capital Management LP, Nexthera Capital LP, Perceptive Advisors LLC, Morgan Stanley, Victory Capital Management Inc. and Granite Point Capital Management L.P.. Company insiders that have bought Zosano Pharma Corp stock in the last two years include Donald J Kellerman, Georgia Erbez, John Peter Walker and Konstantinos Alataris. View Insider Buying and Selling for Zosano Pharma Corp.

How do I buy Zosano Pharma Corp stock?

Shares of Zosano Pharma Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Zosano Pharma Corp stock cost?

One share of Zosano Pharma Corp stock can currently be purchased for approximately $1.49.

Analyst Ratings

Consensus Ratings for Zosano Pharma Corp (NASDAQ:ZSAN) (?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $3.50 (134.90% upside)

Analysts' Ratings History for Zosano Pharma Corp (NASDAQ:ZSAN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/24/2017Piper Jaffray CompaniesInitiated CoverageOverweight$4.00LowView Rating Details
3/11/2017Roth CapitalSet Price TargetBuy$3.00MediumView Rating Details
8/11/2016Ladenburg Thalmann Financial ServicesDowngradeBuy -> NeutralN/AView Rating Details
(Data available from 5/26/2015 forward)

Earnings

Earnings History for Zosano Pharma Corp (NASDAQ:ZSAN)
Earnings by Quarter for Zosano Pharma Corp (NASDAQ:ZSAN)
Earnings History by Quarter for Zosano Pharma Corp (NASDAQ:ZSAN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.30)($0.34)ViewListenView Earnings Details
3/1/2017Q4 2016($0.45)($0.46)ViewN/AView Earnings Details
8/10/2016Q2($0.50)($0.54)ViewN/AView Earnings Details
5/12/2016Q1($0.56)($0.68)ViewListenView Earnings Details
3/29/2016Q4($0.67)($0.64)ViewListenView Earnings Details
11/9/2015Q315($0.61)($0.72)$380.00 millionViewN/AView Earnings Details
8/12/2015Q215($0.53)($0.63)$0.22 million$0.10 millionViewN/AView Earnings Details
3/25/2015($0.64)($1.10)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Zosano Pharma Corp (NASDAQ:ZSAN)
2017 EPS Consensus Estimate: ($1.06)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.43)($0.43)($0.43)
Q2 20171($0.18)($0.18)($0.18)
Q3 20171($0.21)($0.21)($0.21)
Q4 20171($0.24)($0.24)($0.24)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Zosano Pharma Corp (NASDAQ:ZSAN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Zosano Pharma Corp (NASDAQ:ZSAN)
Insider Ownership Percentage: 5.37%
Institutional Ownership Percentage: 41.11%
Insider Trades by Quarter for Zosano Pharma Corp (NASDAQ:ZSAN)
Institutional Ownership by Quarter for Zosano Pharma Corp (NASDAQ:ZSAN)
Insider Trades by Quarter for Zosano Pharma Corp (NASDAQ:ZSAN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/25/2017Georgia ErbezCFOBuy68,000$1.32$89,760.00View SEC Filing  
5/25/2017John Peter WalkerCEOBuy73,716$1.36$100,253.76View SEC Filing  
2/13/2017Enterprise Associates 12 NewMajor ShareholderSell1,099,996$2.01$2,210,991.96View SEC Filing  
9/16/2016Enterprise Associates 12 NewMajor ShareholderSell7,471$0.75$5,603.25View SEC Filing  
9/13/2016Enterprise Associates 12 NewMajor ShareholderSell10,000$0.74$7,400.00View SEC Filing  
8/29/2016M James BarrettMajor ShareholderSell50,000$1.01$50,500.00View SEC Filing  
8/24/2016Enterprise Associates 12 NewMajor ShareholderSell1,200$1.21$1,452.00View SEC Filing  
8/19/2016Donald J KellermanVPBuy15,920$1.32$21,014.40View SEC Filing  
8/19/2016Georgia ErbezCFOBuy47,750$1.32$63,030.00View SEC Filing  
8/19/2016John Peter WalkerDirectorBuy63,700$1.32$84,084.00View SEC Filing  
8/19/2016Konstantinos AlatarisCEOBuy127,389$1.32$168,153.48View SEC Filing  
7/21/2016Enterprise Associates 12 NewMajor ShareholderSell23,681$1.27$30,074.87View SEC Filing  
7/13/2016Enterprise Associates 12 NewMajor ShareholderSell13,382$1.20$16,058.40View SEC Filing  
1/30/2015Enterprise Associates 12 NewMajor ShareholderBuy23,457$11.00$258,027.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Zosano Pharma Corp (NASDAQ:ZSAN)
Latest Headlines for Zosano Pharma Corp (NASDAQ:ZSAN)
Source:
DateHeadline
americanbankingnews.com logoZosano Pharma Corp (ZSAN) Expected to Post Earnings of -$0.17 Per Share
www.americanbankingnews.com - May 26 at 8:55 AM
americanbankingnews.com logoZosano Pharma Corp (ZSAN) CFO Purchases $89,760.00 in Stock
www.americanbankingnews.com - May 25 at 10:21 PM
americanbankingnews.com logoZosano Pharma Corp (ZSAN) CEO Acquires $100,253.76 in Stock
www.americanbankingnews.com - May 25 at 10:21 PM
americanbankingnews.com logoZosano Pharma Corp (ZSAN) Announces Earnings Results, Misses Expectations By $0.04 EPS
www.americanbankingnews.com - May 10 at 5:18 PM
prnewswire.com logoBiotech Stocks Under Scanner -- Bioverativ, Zosano Pharma, MannKind, and Ocera Therapeutics - PR Newswire (press release)
www.prnewswire.com - May 10 at 8:45 AM
streetinsider.com logoZosano Pharma (ZSAN) Reports Q4 Loss of $0.34; CEO Resigns
www.streetinsider.com - May 9 at 9:00 PM
finance.yahoo.com logoInvestor Network: Zosano Pharma Corp. to Host Earnings Call
finance.yahoo.com - May 9 at 9:00 PM
finance.yahoo.com logoZosano Reports First Quarter 2017 Financial Results and Announces Management Changes
finance.yahoo.com - May 9 at 9:00 PM
americanbankingnews.com logoZosano Pharma Corp (ZSAN) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 8 at 9:00 AM
feeds.benzinga.com logoZosano Pharma to Host Conference Call on First Quarter 2017 Financial Results and Provide Operational Update
feeds.benzinga.com - May 8 at 5:43 AM
americanbankingnews.com logoZosano Pharma Corp (ZSAN) Earns Media Impact Rating of -0.12
www.americanbankingnews.com - May 4 at 8:20 AM
americanbankingnews.com logoZosano Pharma Corp (ZSAN) Expected to Post Earnings of -$0.30 Per Share
www.americanbankingnews.com - May 3 at 12:04 AM
americanbankingnews.com logoZosano Pharma Corp (ZSAN) Getting Somewhat Critical News Coverage, Study Finds
www.americanbankingnews.com - April 29 at 9:16 AM
americanbankingnews.com logoShort Interest in Zosano Pharma Corp (ZSAN) Grows By 35.1%
www.americanbankingnews.com - April 29 at 1:17 AM
americanbankingnews.com logoZosano Pharma Corp (ZSAN) Getting Somewhat Favorable News Coverage, AlphaOne Reports
www.americanbankingnews.com - April 25 at 3:11 PM
americanbankingnews.com logoZosano Pharma Corp (ZSAN) Receiving Somewhat Negative Media Coverage, Report Shows
www.americanbankingnews.com - April 20 at 9:17 AM
americanbankingnews.com logoZosano Pharma Corp (ZSAN) Earns Daily Coverage Optimism Rating of -0.10
www.americanbankingnews.com - April 16 at 8:48 AM
americanbankingnews.com logoZosano Pharma Corp (ZSAN) Earning Somewhat Negative News Coverage, Analysis Finds
www.americanbankingnews.com - April 13 at 9:21 AM
americanbankingnews.com logoZosano Pharma Corp (ZSAN) Short Interest Down 12.5% in March
www.americanbankingnews.com - April 12 at 7:17 AM
americanbankingnews.com logo Analysts Anticipate Zosano Pharma Corp (ZSAN) Will Post Earnings of -$0.30 Per Share
www.americanbankingnews.com - April 11 at 6:07 PM
finance.yahoo.com logoShkreli Gives Zosano a Giant Headache
finance.yahoo.com - April 7 at 1:41 PM
americanbankingnews.com logoZosano Pharma Corp (ZSAN) Receives New Coverage from Analysts at Piper Jaffray Companies
www.americanbankingnews.com - March 30 at 8:23 AM
americanbankingnews.com logoZosano Pharma Corp (ZSAN) Short Interest Update
www.americanbankingnews.com - March 28 at 7:07 AM
finance.yahoo.com logoZosano Announces Closing of Public Offering of Common Stock and Exercise of Underwriters’ Over-Allotment Option
finance.yahoo.com - March 23 at 9:09 AM
streetinsider.com logoZosano Pharma (ZSAN) Prices 17M Common Stock Offering at $1.50/Share
www.streetinsider.com - March 18 at 7:46 PM
streetinsider.com logoZosano Pharma (ZSAN) Files Prelim. Prospective for 17M Common Stock Offering Priced at $1.50/Share - StreetInsider.com
www.streetinsider.com - March 17 at 3:36 PM
finance.yahoo.com logoZosano Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - March 17 at 3:36 PM
finance.yahoo.com logo9:26 am Zosano Pharma prices 17,000,000 share offering at $1.50/share
finance.yahoo.com - March 17 at 3:36 PM
americanbankingnews.com logoZosano Pharma Corp (ZSAN) Given a $3.00 Price Target at Roth Capital
www.americanbankingnews.com - March 12 at 9:27 PM
globenewswire.com logoZosano Pharma Reports Fourth Quarter and Fiscal 2016 Financial Results and Business Update - GlobeNewswire (press release)
globenewswire.com - March 1 at 8:02 AM
seekingalpha.com logoZosano Pharma: There Is More Upside Despite Recent Run-Up
seekingalpha.com - February 28 at 10:51 AM
benzinga.com logoHow Did Today's Zosano Pharma Short Call From Martin Shkreli Play Out?
www.benzinga.com - February 14 at 7:17 AM
streetinsider.com logoZosano Pharma (ZSAN) Says 3.8mg Dose of M207 Meets Both Co-primary Endpoints in the ZOTRIP Pivotal Efficacy Trial in Migraine
www.streetinsider.com - February 14 at 7:17 AM
finance.yahoo.com logoCan Zosano Pharma Turn Itself Around With This Late-Stage Migraine Trial Win?
finance.yahoo.com - February 14 at 7:17 AM
biz.yahoo.com logoZOSANO PHARMA CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - February 14 at 7:17 AM
biz.yahoo.com logoZOSANO PHARMA CORP Files SEC form 8-K, Other Events
biz.yahoo.com - January 26 at 6:40 AM
finance.yahoo.com logoZosano Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - January 24 at 5:46 AM
streetinsider.com logoZosano Pharma (ZSAN) Reports Sale of Non-Strategic Asset
www.streetinsider.com - November 23 at 8:50 PM
biz.yahoo.com logoZOSANO PHARMA CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - November 22 at 8:46 PM
seekingalpha.com logoNew owners take the reins at Zosano Pharma
seekingalpha.com - November 21 at 9:05 PM
finance.yahoo.com logoZOSANO PHARMA CORP Financials
finance.yahoo.com - November 17 at 8:10 PM
biz.yahoo.com logoZOSANO PHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi
biz.yahoo.com - November 9 at 8:45 PM
streetinsider.com logoZosano Pharma (ZSAN) Completes Enrollment in Zotrip Trial
www.streetinsider.com - November 8 at 8:36 PM
biz.yahoo.com logoZOSANO PHARMA CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
biz.yahoo.com - November 3 at 8:37 PM
biz.yahoo.com logoZOSANO PHARMA CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
biz.yahoo.com - October 14 at 8:02 PM
finance.yahoo.com logoSHAREHOLDER NOTICE: Khang & Khang LLP Announces an Investigation of Zosano Pharma Corporation and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - October 6 at 5:14 AM

Social

Chart

Zosano Pharma Corp (ZSAN) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by MarketBeat.com Staff